Nicholas Chi-Kwan Ling

Title: Innovations of Nicholas Chi-Kwan Ling

Introduction

Nicholas Chi-Kwan Ling is a prominent inventor based in San Diego, CA. He has made significant contributions to the field of biologics detection, holding a total of 8 patents. His work focuses on developing sensitive and specific assays that enhance the detection of biologics in patient samples.

Latest Patents

One of his latest patents is titled "Indirect homogeneous mobility shift assays for the detection of biologics in patient samples." This invention provides a sensitive and specific indirect homogeneous mobility shift assay using size exclusion chromatography to measure biologics such as vedolizumab and ustekinumab in patient samples. The assays are particularly advantageous for detecting the presence or level of biologics that target complex or large antigens, including cell surface proteins, transmembrane proteins, heavily glycosylated proteins, and multimeric proteins. Additionally, the invention addresses antigens that cannot be purified, impure antigens, and partially or substantially purified antigens. It also provides isolated soluble α4β7 integrin heterodimers and isolated soluble IL-12p40 monomers suitable for use in the indirect assays described.

Career Highlights

Throughout his career, Nicholas has worked with notable companies such as Nestec S.a. and Precision Ibd, Inc. His innovative approaches have significantly impacted the field of biologics and diagnostics.

Collaborations

Nicholas has collaborated with talented individuals, including Sharat Singh and Jared Salbato, contributing to the advancement of his research and inventions.

Conclusion

Nicholas Chi-Kwan Ling's work in the development of indirect homogeneous mobility shift assays represents a significant advancement in the detection of biologics. His contributions continue to influence the field and improve patient diagnostics.